PRESS-RELEASE ·Filed Apr 30, 2026
Press release: earnings
Actionable Insight • Neutral
Monitor for upcoming clinical trial catalysts or financing events; no immediate trading signal from this earnings release.
Final — all horizons settled through T+60d
VCNX ▲ +51.28% at T+60d
NEUTRAL call ✓ call won +51.28% · α vs SPY +48.17% · entry $0.7800 → $1.18
T+1d
+28.21%
call +28.21% · α +27.99%
$1.00
settled 5mo ago
T+5d
+29.49%
call +29.49% · α +27.76%
$1.01
settled 5mo ago
T+20d
+28.21%
call +28.21% · α +22.98%
$1.00
settled 4mo ago
T+60d
+51.28%
call +51.28% · α +48.17%
$1.18
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Vaccinex released financial results for the year ended December 31, 2025, reporting an EPS of -$1.09 for Q3 2023, which was in line with consensus estimates. As a clinical-stage biotech with no revenue, the filing is routine and lacks material financial surprises or guidance changes.
Key Financial Metrics
EPS
$-1.09
Revenue
$0.00
est $0.00
Rating
in line
Key Facts
- EPS of -$1.09 for Q3 2023, in line with consensus
- No revenue reported for the period
- Clinical-stage company with no approved products or revenue stream
- Financial statements posted on company website
Financial Impact
No material financial impact; clinical-stage biotech with no revenue and EPS in line with expectations
eps
Risk Factors
- No revenue or near-term commercialization path
- Dependence on future financing for clinical development
Market Snapshot
Exchange
OTC
Sector
Pharmaceutical Preparations
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284388 |
US Market Status
Market Open — Closes in 32m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access